- Disease: Post-COVID-19
- Study type: Randomised Clinical Trial
- Study type descriptors: Interventional, Single centre
- Study aim: To determine whether Nicotinamide Riboside and/or Mind-Body Reprocessing Therapy increase health-related quality of life in individuals with long COVID compared with care as usual and/or placebo
- Number of participants enrolled: 310
- Study enrolling from to
- Study includes follow-up for 3 months
Study Data
- Adults
- General population
- Elderly
- Community
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Dietary
- Psychotherapy
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to